01587nam 2200421Ia 450 991069905120332120090821133637.0(CKB)5470000002399374(OCoLC)432321584(EXLCZ)99547000000239937420090821d2004 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] IND exemptions for studies of lawfully marketed drug or biological products for the treatment of cancerRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,[2004]1 online resource (8 pages)"Center for Biologics Evaluation and Research (CBER).""Clinical medical.""Revision 1.""January 2004."Guidance for industry Medicine, ExperimentalGovernment policyUnited StatesClinical trialsGovernment policyUnited StatesCancerTreatmentUnited StatesMedicine, ExperimentalGovernment policyClinical trialsGovernment policyCancerTreatmentCenter for Drug Evaluation and Research (U.S.)Center for Biologics Evaluation and Research (U.S.)GPOGPOBOOK9910699051203321Guidance for industry3434577UNINA